GILD — Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Total Product Sales: $7.9 billion, up 5% year-over-year; $7.7 billion excluding Vecluri, up 7%.
• Full-Year 2025 Total Product Sales: $28.9 billion, a 1% increase from 2024, exceeding guidance of $28.4-$28.7 billion; $28 billion excluding Vecluri, up 4%.
• HIV Sales: $20.8 billion for 2025, up 6% year-over-year; Q4 HIV sales reached $5.8 billion, up 6%.
• Liver Disease Sales: $3.2 billion for 2025, up 6% year-over-year; Q4 liver sales were $844 million, up 17%.
• Cell Therapy Sales: $1.8 billion for 2025, down 7% year-over-year; Q4 sales were $458 million, down 6%.
• Non-GAAP Diluted EPS: $8.15 for 2025, within guidance of $8.25-$8.50.

2. Strategic Updates and Business Highlights:

• HIV Portfolio Growth: Biktarvy and Descovy drove strong growth; YES2GO, a new injectable HIV prevention drug, exceeded coverage goals and is expected to significantly contribute to future sales.
• Pipeline Advancements: Gilead has a robust pipeline with multiple upcoming launches, including Trodelvy for first-line metastatic triple-negative breast cancer and Anidocel for multiple myeloma.
• Operational Discipline: Continued focus on expense management with R&D expenses down 1% and SG&A expenses down 5% compared to 2024.

3. Forward Guidance and Outlook:

• 2026 Total Product Sales Guidance: Expected between $29.6 billion and $30 billion, with base business sales growth of 4-5%.
• HIV Sales Growth: Anticipated to grow approximately 6% in 2026, with YES2GO projected to generate around $800 million in revenue.
• Cell Therapy Revenue Decline: Expected to decrease by approximately 10% in 2026 due to competitive pressures.

4. Bad News, Challenges, or Points of Concern:

• Impact of Medicare Part D Redesign: Estimated $900 million headwind affecting overall growth.
• Vecluri Sales Decline: Revenue dropped significantly, down 49% year-over-year, reflecting lower COVID-19 hospitalization rates.
• Competitive Pressures in Cell Therapy: Ongoing competition is expected to continue impacting sales negatively.
• Drug Pricing Agreement Impact: Anticipated headwinds from new drug pricing agreements and potential shifts to lower price channels.

5. Notable Q&A Insights:

• YES2GO Growth Expectations: Management is optimistic about YES2GO's potential, expecting strong growth despite early-stage adoption challenges.
• Anidocel Market Positioning: Anticipated to become a market leader in the fourth-line multiple myeloma space due to its efficacy and safety profile.
• Trodelvy Use in First-Line Setting: There is observed off-label use in the first-line setting, supported by positive trial results and NCCN recommendations, which could significantly expand its market opportunity.
• Long-Acting HIV Treatments: Gilead is developing multiple long-acting HIV therapies, with a focus on differentiating their products from competitors.

Overall, Gilead Sciences, Inc. reported solid financial performance in 2025, driven by strong growth in its HIV portfolio and a promising pipeline of new therapies. However, it faces challenges from competitive pressures and regulatory changes that could impact future growth.